Love Tara M, Anaya Daniel A, Prime Matthew S, Ardolino Luke, Ekinci Okan
Roche Information Solutions, Roche Diagnostics Corporation, Santa Clara, California, United States of America.
Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, United States of America.
PLoS One. 2022 May 13;17(5):e0268477. doi: 10.1371/journal.pone.0268477. eCollection 2022.
Molecular tumor boards (MTBs) require specialized activities to leverage genomic data for therapeutic decision-making. Currently, there are no defined standards for implementing, executing, and tracking the impact of MTBs. This study describes the development and validation of ACTE-MTB, a tool to evaluate the maturity of an organization's MTB to identify specific areas that would benefit from process improvements and standardization. The ACTE-MTB maturity assessment tool is composed of 3 elements: 1) The ACTE-MTB maturity model; 2) a 59-question survey on MTB processes and challenges; and 3) a 5-level MTB maturity scoring algorithm. This tool was developed to measure MTB maturity in the categories of Access, Consultation, Technology, and Evidence (ACTE) and was tested on 20 MTBs spanning the United States, Europe, and Asia-Pacific regions. Validity testing revealed that the average maturity score was 3.3 out of 5 (+/- 0.1; range 2.0-4.3) with MTBs in academic institutions showing significantly higher overall maturity levels than in non-academic institutions (3.7 +/- 0.2 vs. 3.1 +/- 0.2; P = .018). While maturity scores for academic institutions were higher for Consultation, Technology, and Evidence domains, the maturity score for the Access domain did not significantly differ between the two groups, highlighting a disconnect between MTB operations and the downstream impact on ability to access testing and/or therapies. To our knowledge, ACTE-MTB is the first tool of its kind to enable structured, maturity assessment of MTBs in a universally-applicable manner. In the process of establishing construct validity of this tool, opportunities for further investigation and improvements were identified that address the key functional areas of MTBs that would likely benefit from standardization and best practice recommendations. We believe a unified approach to assessment of MTB maturity will help to identify areas for improvement at both the organizational and system level.
分子肿瘤委员会(MTB)需要开展专门活动,以便利用基因组数据进行治疗决策。目前,在MTB的实施、执行和跟踪其影响方面,尚无明确的标准。本研究描述了ACTE-MTB的开发与验证过程,ACTE-MTB是一种评估组织MTB成熟度的工具,用于识别那些将从流程改进和标准化中受益的特定领域。ACTE-MTB成熟度评估工具由三个要素组成:1)ACTE-MTB成熟度模型;2)一份关于MTB流程和挑战的包含59个问题的调查问卷;3)一种五级MTB成熟度评分算法。该工具旨在衡量MTB在获取、会诊、技术和证据(ACTE)方面的成熟度,并在美国、欧洲和亚太地区的20个MTB上进行了测试。效度测试显示,平均成熟度得分为3.3(满分5分,±0.1;范围2.0 - 4.3),学术机构的MTB总体成熟度水平显著高于非学术机构(3.7±0.2对3.1±0.2;P = 0.018)。虽然学术机构在会诊、技术和证据领域的成熟度得分较高,但两组在获取领域的成熟度得分没有显著差异,这凸显了MTB运营与对获取检测和/或治疗能力的下游影响之间的脱节。据我们所知,ACTE-MTB是同类工具中首个能够以普遍适用的方式对MTB进行结构化成熟度评估的工具。在确立该工具的结构效度过程中,发现了进一步调查和改进的机会,这些机会涉及MTB可能从标准化和最佳实践建议中受益的关键功能领域。我们相信,统一的MTB成熟度评估方法将有助于识别组织和系统层面的改进领域。